Fungal Endophthalmitis. Literature Review
https://doi.org/10.18008/1816-5095-2020-3S-556-565
Abstract
Fungal endophthalmitis is an extremely “severe” pathology that can lead not only to the loss of the eye as an organ, but in some cases, the death of the patient. This disease can be attributed to a disease that has a “mask” in some of its manifestations, since it can often mimic bacterial inflammation or an atypical reaction of the vascular membrane after surgery. Questions of diagnostics, and especially differential diagnostics, often cause difficulties for practitioners, while the situation is burdened by rather poorly developed methods of routine bacteriological research, and even more so by highly specific methods, such as enzyme immunoassay or polymerase chain reaction. At the same time, in most medical institutions, even in big cities, due to the rarity of pathology, the mechanisms of interaction between services (for example, sending material) are not worked out properly. For a practicing surgeon who is not engaged in eye infectious diseases, and especially inflammatory retinology, it is extremely difficult to make a correct diagnosis, which, unfortunately, very often directs the doctor on the wrong path of diagnosis and treatment. In addition, some modern fungicides, unfortunately, do not have permits for their active study and use in ophthalmological practice. A number of these factors can significantly hinder scientific and clinical progress in the treatment of this terrible and often tragic disease. To highlight these issues, an overview of the current state of the problem of clinic, diagnosis, differential diagnosis and treatment of fungal endophthalmitis, which is an extremely important medical, economic and social dilemma, is presented. The paper also covers the definition of endophthalmitis, classification, life cycle, factors of aggression and invasion of fungal microorganisms, the basics of pathological physiology of the spread of fungal infection.
About the Authors
V. N. Kazaykin
Ekaterinburg Center IRTC “Eye Microsurgery”
Russian Federation
Russian Federation
MD, eye surgeon, Head of Vitreoretinal Department
Academician Bardin str., 4A, Ekaterinburg, 620149, Russian Federation
V. O. Ponomarev
Ekaterinburg Center IRTC “Eye Microsurgery”
Russian Federation
Russian Federation
PhD, eye surgeon, Head of Diagnostic Department
Academician Bardin str., 4A, Ekaterinburg, 620149, Russian Federation
References
1. Nedzveckaja O.V. Infectious endophthalmitis (intraocular wound infection). Еmergency medicine = Medicina neolozhnyh sostojanij. 2010;(31)6:34–37 (In Russ.).
2. Belyj Yu.A., Tereshhenko A.V., Judina N.N. Experimental justification of safe concentrations of sodium hypochloride electrolytic solution for intraocular administration. Bulletin of Orenburg state University = Vestnik Orenburgskogo gosudarstvennogo universiteta. 2004;4:191–195 (In Russ.).
3. Juzhakov A.M., Gundorova R.A., Neroev V.V., Stepanov A.V. Intraocular wound infection: A guide for doctors. Moscow: Medical information Agency; 2007:83 (In Russ.).
4. Barry P., Cordoves L., Gardner S. ESCRS Guidelines for Prevention and Treatment of Endopthalmitis Following Cataract Surgery. Co Dublin: Temple House, Temple Road, Blackrock. 2013:1–22.
5. Durand M.L. The post — Endophthalmitis Vitrectomy Study era. Arch. Ophthalmol. 2002;120(2):233–234.
6. Flinn H.W. Jr., Batra N.R. Endophthalmitis in Clinical Practice. Springer. 2017:1–18.
7. Durand M.L. Bacterial and Fungal Endophthalmitis. Clin. Microbiol. Rev. 2017;30(3):597–613. DOI: 10.1128/CMR.00113‑16
8. Fazakas A. Summarizing report on the personal ophthalmological examinations of the fungi. Ophthalmologica. 1953;126(2):91–109.
9. Hammeke J.C., Ellis P.P. Mycotic flora of the conjunctiva. Am. J. Ophthalmol. 1960;49:1174–1178. DOI: 10.1016/0002‑9394(60)91632‑9
10. Ainley R., Smith B. Fungal flora of the conjunctival sac in healthy and diseased eyes. Br. J. Ophthalmol. 1965;49(10):505–515. DOI: 10.1136/bjo.49.10.505
11. Ando N., Takatori K. Fungal flora of the conjunctival sac. Am. J. Ophthalmol. 1982;94(1):67–74. DOI: 10.1016/0002‑9394(82)90193‑3
12. Toth J., Bausz M., Imre L. Unilateral Malassezia furfur blepharitis after perforating keratoplasty. Br. J. Ophthalmol. 1996;80(5):488. DOI: 10.1136/bjo.80.5.488
13. Pine L., Shearin W.A., Gonzales C.A. Mycotic flora of the lacrimal duct. Am. J. Ophthalmol. 1961;52:619–625.
14. Muccioli C., Belfort R. Jr., Neves R., Limbal and choroidal Cryptococcus infection in the acquired immunodeficiency syndrome. Am. J. Ophthalmol. 1995;120(4):539–540. DOI: 10.1016/s0002‑9394(14)72677‑7
15. Jani B.R., Rinaldi M.G., Reinhart W.J. An unusual case of fungal keratitis: Metarrhizium anisopliae. Cornea. 2001;20(7):765–768. DOI: 10.1097/00003226‑200110000‑00020
16. Hemady R., Sainz de la Maza M., Raizman M.B., Six cases of scleritis associated with systemic infection. Am. J. Ophthalmol. 1992;114(1):55–62. DOI: 10.1016/s0002‑9394(14)77413‑6
17. Sinskey R.M., Anderson W.B. Miliary blastomycosis with metastatic spread to posterior uvea of both eyes. AMA Arch. Ophthalmol. 1955;54(4):602–604.
18. Tereshhenko A.V., Trifanenkova I.G., Okuneva M.V. Fungal endophthalmitis. Ophthalmosurgery = Oftal’mohirurgija. 2019;2:70–75 (In Russ.). DOI: 10.25276/0235‑4160‑2019‑2‑70‑75
19. McLaughlin D.J., Spatafora J.W. (eds). The Mycota 7. Systematics and Evolution part A. Springer, Heidelberg. 2014.
20. Tedersoo L., Sanchez‑Ramirez S., Koljalg U. High‑level classification of the Fungi and a tool for evolutionary ecological analyses. Fungal Diversity. 2018;90:135–159. DOI: 10.1007/s13225‑018‑0401‑0
21. Baron S. Medical Microbiology 4th Edition. Univ. of Texas Medical Branch. 1996:1273.
22. Essman T.F., Flynn H.W. Jr., Smiddy W.E., Treatment outcomes in a 10‑year study of endogenous fungal endophthalmitis. Ophthalmic Surg. Lasers. 1997;28(3):185–194.
23. Somov E.E. Clinical ophthalmology. Moscow: MEDpress‑inform, 2008:392 (In Russ.).
24. Sridhar J., Flynn H., Jr., Kuriyan А. Endogenous fungal endophthalmitis: risk factors, clinical features, and treatment outcomes in mold and yeast infections. J. Ophthalmic Inflamm. Infect. 2013;3(1):60. DOI: 10.1186/1869‑5760‑3‑60
25. Rao N.A., Hidayat A.A. Endogenous mycotic endophthalmitis: variations in clinical and histopathologic changes in candidiasis compared with aspergillosis. Am. J. Ophthalmol. 2001;3(2):244–251. DOI: 10.1016/s0002‑9394(01)00968‑0
26. Schiedler V., Scott I.U., Flynn H.W. Jr. Culture‑proven endogenous endophthalmitis: clinical features and visual acuity outcomes. Am. J. Ophthalmol. 2004;3(4):725–731. DOI: 10.1016/j.ajo.2003.11.013
27. Klotz S.A., Penn C.C., Negvesky G.J., Fungal and parasitic infections of the eye. Clin. Microbiol. Rev. 2000;13(4):662–685. DOI: 10.1128/cmr.13.4.662‑685.2000
28. Rao N.A., Hidayat A. A. Comparative clinicopathologic study of endogenous mycotic endophthalmitis: variations in clinical and histopathologic changes in candidiasis compared to aspergillosis. Trans. Am. Ophthalmol. Soc. 2000;98:183–193. Discussion 193–194.
29. Lundquist O., Osterlin S. Glucose concentration in the vitreous of nondiabetic and diabetic human eyes. Graefes Arch. Clin. Exp. Ophthalmol. 1994;232(2):71–74. DOI: 10.1007/BF00171666
30. Kato H., Yoshimura Y., Suido Y. Prevalence of, and risk factors for, hematogenous fungal endophthalmitis in patients with Candida bloodstream infection. Infection. 2018;46(5):635–640. DOI: 10.1007/s15010‑018‑1163‑z
31. Lei B., Jiang R., Gu R. Endogenous Fungal Endophthalmitis Associated with Genitourinary Procedures. Ocul. Immunol. Inflamm. 2019:27(5):747–755. DOI: 10.1080/09273948.2018.1465100
32. Kloess P.M., Stulting R.D., Waring G.O. 3rd. Bacterial and fungal endophthalmitis after penetrating keratoplasty. Am. J. Ophthalmol. 1993;115(3):309–316. DOI: 10.1016/s0002‑9394(14)73580‑9
33. Solomon R., Donnenfeld E.D., Azar D.T. Infectious keratitis after laser in situ keratomileusis: results of an ASCRS survey // Journal of Cataract and Refractive Surgery. 2003; 29(10): 2001‑2006. DOI: 10.1016/s0886‑3350(03)00512‑1
34. Sridhar M.S., Garg P., Bansal A.K. Fungal keratitis after laser in situ keratomileusis. Journal of Cataract and Refractive Surgery. 2000;26(4):613–615. DOI: 10.1016/s0886‑3350(99)00459‑9
35. Gupta A., Srinivasan R., Kaliaperumal S.,Post‑traumatic fungal endophthalmitis — a prospective study. Eye (Lond). 2008;22(1):13– 17. DOI: 10.1038/sj.eye.6702463
36. Naumann G., Green W.R., Zimmerman L.E. Mycotic keratitis. A histopathologic study of 73 cases. Am. J. Ophthalmol. 1967;64(4):668–682.
37. Chang S.W., Tsai M.W., Hu F.R. Deep Alternaria keratomycosis with intraocular extension. Am. J. Ophthalmol. 1994;117(4):544–545. DOI: 10.1016/s0002‑9394(14)70025‑x
38. Smith T.C., Benefield R.J., Kim J.H. Risk of Fungal Endophthalmitis Associated with Cataract Surgery: A Mini‑Review. Mycopathologia. 2015;180(5–6):291–297. DOI: 10.1007/s11046‑015‑9932‑z
39. Mikosz C.A., Smith R.M., Kim M. Fungal endophthalmitis associated with compounded products. Emerg. Infect. Dis. 2014;20(2):248–256. DOI: 10.3201/eid2002.131257
40. Strausbaugh L.J., Sewell D.L., Ward T.T. High frequency of yeast carriage on hands of hospital personnel. J. Clin. Microbiol. 1994;32:2299–2300.
41. AlHadlaq A., AlMalki S., AlShahwana S. Late onset endophthalmitis associated with unexposed glaucoma valved drainage device. Saudi J. Ophthalmol. 2016;30(2):125–127. DOI: 10.1016/j.sjopt.2015.12.005
42. Palioura S., Relhan N., Leung E. Delayed‑onset Candida parapsilosis cornea tunnel infection and endophthalmitis after cataract surgery: Histopathology and clinical course. Am. J. Ophthalmol. Case. Rep. 2018;11:109–114. DOI: 10.1016/j.ajoc.2018.06.011
43. Bhavsar A.R. Vitreoretinal’naja hirurgija. Moscow: Logosfera; 2013:259–264 (In Russ.).
44. Maljugin B.E., Shpak A.A., Morozova T.A. Pharmacological support of modern cataract surgery. Moscow: Ophthalmology; 2010:14–15 (In Russ.).
45. Barry P., Cordoves L., Gardner S. ESCRS Guidelines for Prevention and Treatment of Endopthalmitis Following Cataract Surgery. Co Dublin: Temple House, Temple Road, Blackrock. 2013:1–22.
46. Novickaja I.V., Somova V.V. On the issue of detecting fungal eye infection. Advances in medical Mycology = Uspehi medicinskoj mikologii. 2005;14:156–159 (In Russ.).
47. Breit S.M., Hariprasad S.M., Mieler W.F. Management of endogenous fungal endоftalmitis with voriconazole and caspofungin. Am. J. Ophthalmol. 2005;139(1):135–140. DOI: 10.1016/j.ajo.2004.08.077
48. Pappas P.G., Kauffman C.A., Andes D. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect Dis. 2009;48:503–535. DOI: 10.1086/596757
49. Walsh T.J., Anaissie E.J., Denning D.W. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 2008;46:327–360. DOI: 10.1086/525258
50. O’Day D.M., Head W.S., Robinson R.D. Intraocular penetration of systemically administered antifungal agents. Curr. Eye Res. 1985;4(2):131–134. DOI: 10.3109/02713688508999978
51. Louie A., Liu W., Miller D.A. Efficacies of high‑dose fluconazole plus amphotericin B and high‑dose fluconazole plus 5‑fluorocytosine versus amphotericin B, fluconazole, and 5‑fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans. Antimicrob. Agents Chemother. 1999;43(12):2831–2840.
52. Naidoff M.A., Green W.R. Endogenous Aspergillus endophthalmitis occurring after kidney transplant. Am. J. Ophthalmol. 1975;79(3):502–509. DOI: 10.1016/0002‑9394(75)90628‑5
53. Roney P., Barr C., Chun C. Endogenous Aspergillus endophthalmitis. Rev. Infect. Dis. 1986;8(6):955–958. DOI: 10.1093/clinids/8.6.955
54. Weishaar P.D., Flynn H.W., Jr., Murray T.G. Endogenous Aspergillus endophthalmitis: clinical features and treatment outcomes. Ophthalmology. 1998;105(1):57–65. DOI: 10.1016/s0161‑6420(98)71225‑3
55. Axelrod A.J., Peyman G.A., Apple D.J. Toxicity of intravitreal injection of amphotericin B. Am. J. Ophthalmol. 1973;76(4):578–583. DOI: 10.1016/0002‑9394(73)90753‑8
56. Souri E.N., Green W.R., Intravitreal amphotericin B toxicity. Am. J. Ophthalmol. 1974;78(1):77–81. DOI: 10.1016/0002‑9394(74)90012‑9
57. Green W.R., Bennett J.E., Goos R.D. Ocular penetration of amphotericin B: a report of laboratory studies and a case report of postsurgical Cephalosporium endophthalmitis. Arch. Ophthalmol. 1965;73:769–775. DOI: 10.1001/ar‑chopht.1965.00970030771004
58. Goldblum D., Rohrer K., Frueh B.E. Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model. Antimicrob. Agents Chemother. 2002;46(12):3719–3723. DOI: 10.1128/AAC.46.12.3719‑3723.2002
59. Cannon J.P., Fiscella R., Pattharachayakul S. Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model. Invest. Ophthalmol. Vis. Sci. 2003;44(5):2012–2017. DOI: https://doi.org/10.1167/iovs.02‑1020
60. O’Day D.M., Foulds G., Williams T.E., Ocular uptake of fluconazole following oral administration. Arch. Ophthalmol. 1990;108(7):1006–1008. DOI: 10.1001/archopht.1990.01070090108050
61. Schulman J.A., Peyman G., Fiscella R. Toxicity of intravitreal injection of fluconazole in the rabbit. Can. J. Opthalmol. 1987;22(6):304–306.
62. Wingard L.B., Jr., Zuravleff J.J., Doft B.H. Intraocular distribution of intravitreal administered amphotericin B in normal and vitrectomized eyes. Invest. Ophthalmol. Vis. Sci. 1989;30:2184–2189.
63. Kernt M., Neubauer A.S., De Kaspar H.M. Intravitreal voriconazole: in vitro safety‑profile for fungal endophthalmitis. Retina. 2009;29(3):362–370. DOI: 10.1097/IAE.0b013e31818d4b9b
64. Gao H., Pennesi M.E., Shah K. Intravitreal voriconazole: an electroretinographic and histopathologic study. Arch. Ophthalmol. 2004;122(11):1687–1692. DOI: 10.1001/archopht.122.11.1687
65. Shen Y.C., Wang M.Y., Wang C.Y. Clearance of intravitreal voriconazole. Invest. Ophthalmol. Vis. Sci. 2007;48(5):2238–2241. DOI: 10.1167/iovs.06‑1362
66. Sponsel W.E., Graybill J.R., Nevarez H.L. Ocular and systemic posaconazole (SCH‑56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br. J. Ophthalmol. 2002;86(7):829–830. DOI: 10.1136/bjo.86.7.829‑a
67. Gharaghani M., Hivary S., Taghipour S. Luliconazole, a highly effective imidazole, against Fusarium species complexes. Med. Microbiol. Immunol. 2020. [Epub ahead of print].
68. Yoshizumi M.O., Banihashemi A.R. Experimental intravitreal ketoconazole in DMSO. Retina. 1988;8(3):210–215. DOI: 10.1097/00006982‑198808030‑00012
69. Morris M.I., Villmann M. Echinocandins in the management of invasive fungal infections, part 1. Am. J. Health Syst. Pharm. 2006;63(18):1693–1703. DOI: 10.2146/ajhp050464.p1
70. Groll A.H., Gullick B.M., Petraitiene R. Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK‑0991) in rabbits. Antimicrob. Agents Chemother. 2001;45(2):596–600. DOI: 10.1128/AAC.45.2.596‑600.2001
71. Harrison J.M., Glickman R.D., Ballentine C. Retinal function assessed by ERG before and after induction of ocular aspergillosis and treatment by the anti‑fungal, micafungin, in rabbits. Doc. Ophthalmol. 2005;110(1):37–55. DOI: 10.1007/s10633‑005‑7342‑0
72. Chhablani J. Fungal endophthalmitis. Expert Rev. Anti. Infect. Ther. 2011;;9(12):1191–1201. DOI: 10.1586/eri.11.139
Review
For citations:
Kazaykin V.N., Ponomarev V.O. Fungal Endophthalmitis. Literature Review. Ophthalmology in Russia. 2020;17(3s):556-565. (In Russ.) https://doi.org/10.18008/1816-5095-2020-3S-556-565
Views:
818
Email this article 